Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia.

IF 8.2 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2025-02-05 DOI:10.1093/cid/ciae332

Sunish Shah, Ellen G Kline, Ghady Haidar, Kevin M Squires, Jason M Pogue, Erin K McCreary, Justin Ludwig, Lloyd G Clarke, Madison Stellfox, Daria Van Tyne, Ryan K Shields

引用次数: 0

Abstract

Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs 10%; P = .002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.

查看原文本刊更多论文

耐多药铜绿假单胞菌菌血症或肺炎患者对头孢唑肟-阿维菌素和头孢洛赞-他唑巴坦的耐药率。

在对多种药物产生耐药性的铜绿假单胞菌菌血症或肺炎的连续患者中，我们发现使用头孢他啶-阿维菌素治疗的患者比使用头孢妥赞-他唑巴坦治疗的患者更容易产生耐药性（定义为 MIC 增加≥4 倍）（40% 对 10%; P=0.002）。头孢唑肟-阿维巴坦的耐药性与安培C和外排调控通路中的新突变有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.